ISCO
International Stem Cell Corporation
Price Chart
Latest Quote
$0.18
+0.01 (+5.88%)
Current Price
| Previous Close | $0.17 |
| Open | $0.19 |
| Day High | $0.19 |
| Day Low | $0.19 |
| Volume | 5,266 |
Stock Information
| Shares Outstanding | 8.00M |
| Total Debt | $3.52M |
| Cash Equivalents | $933K |
| Revenue | $9.29M |
| Net Income | $-382K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.44M |
| EPS (TTM) | $-0.05 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.32M |
| Sales | $9.29M |
| Income | $-382K |
| Book/sh | $-0.53 |
| Cash/sh | $0.12 |
| Employees | 33 |
Financial Ratios
| Quick Ratio | 0.35 |
| Current Ratio | 0.76 |
| Debt/Eq | 4190.48 |
Returns & Margins
| ROA | -2.81% |
| ROE | -256.38% |
| Gross Margin | 56.98% |
| Operating Margin | -8.21% |
| Profit Margin | -4.11% |
Ownership
| Insider Ownership | 53.77% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.20 |
| P/S | 0.16 |
| P/B | -0.34 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.17 |
| SMA50 | $0.17 |
| SMA200 | $0.15 |
| RSI | 50.00 |
| ATR | 0.0057 |
| Shares Float | 3.70M |
| Volatility | 0.01 |
| Rel Volume | 11.67 |
Performance History
| Week | +5.88% |
| Month | +5.88% |
| Quarter | +28.57% |
| 6 Months | +28.57% |
| YTD | +28.57% |
| Year | +20.00% |
| 3 Years | +38.46% |
| 5 Years | -48.57% |
| 10 Years | -90.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.18 | 15,000 |
| 2026-06-23 | $0.17 | 0 |
| 2026-06-22 | $0.17 | 1,000 |
| 2026-06-18 | $0.17 | 0 |
| 2026-06-17 | $0.17 | 0 |
| 2026-06-16 | $0.17 | 1,400 |
| 2026-06-15 | $0.17 | 0 |
| 2026-06-12 | $0.17 | 0 |
| 2026-06-11 | $0.17 | 1,100 |
| 2026-06-10 | $0.17 | 3,400 |
| 2026-06-09 | $0.18 | 0 |
| 2026-06-08 | $0.18 | 0 |
| 2026-06-05 | $0.18 | 0 |
| 2026-06-04 | $0.18 | 0 |
| 2026-06-03 | $0.18 | 1,000 |
| 2026-06-02 | $0.17 | 600 |
| 2026-06-01 | $0.17 | 2,000 |
| 2026-05-29 | $0.17 | 200 |
| 2026-05-28 | $0.17 | 0 |
| 2026-05-27 | $0.17 | 0 |
| 2026-05-26 | $0.17 | 0 |
About International Stem Cell Corporation
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It serves professional and retail customers. The company was founded in 2001 and is headquartered in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ISCO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,764,000 | $3,181,000 | $3,269,000 | $2,935,000 |
| Cost Of Revenue | $3,764,000 | $3,181,000 | $3,269,000 | $2,935,000 |
| Total Revenue | $9,085,000 | $7,789,000 | $8,180,000 | $7,176,000 |
| Operating Revenue | $9,085,000 | $7,789,000 | $8,180,000 | $7,176,000 |
| Expenses | ||||
| Interest Expense | $145,000 | $139,000 | $135,000 | $128,000 |
| Total Expenses | $9,153,000 | $8,452,000 | $8,363,000 | $9,097,000 |
| Other Income Expense | $4,000 | $671,000 | $-13,000 | $1,150,000 |
| Other Non Operating Income Expenses | $4,000 | $8,000 | $-13,000 | $13,000 |
| Net Non Operating Interest Income Expense | $-145,000 | $-139,000 | $-135,000 | $-128,000 |
| Interest Expense Non Operating | $145,000 | $139,000 | $135,000 | $128,000 |
| Operating Expense | $5,389,000 | $5,271,000 | $5,094,000 | $6,162,000 |
| Selling And Marketing Expense | $1,216,000 | $1,246,000 | $1,245,000 | $1,383,000 |
| General And Administrative Expense | $3,516,000 | $3,514,000 | $3,357,000 | $4,084,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Net Interest Income | $-145,000 | $-139,000 | $-135,000 | $-128,000 |
| Normalized Income | $-209,000 | $-794,000 | $-331,000 | $-2,036,000 |
| Net Income From Continuing And Discontinued Operation | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Total Operating Income As Reported | $-68,000 | $-663,000 | $-183,000 | $-1,921,000 |
| Net Income Common Stockholders | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Net Income | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Net Income Including Noncontrolling Interests | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Net Income Continuous Operations | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Pretax Income | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Special Income Charges | $0 | $663,000 | $0 | $1,137,000 |
| Operating Income | $-68,000 | $-663,000 | $-183,000 | $-1,921,000 |
| Gross Profit | $5,321,000 | $4,608,000 | $4,911,000 | $4,241,000 |
| Per Share | ||||
| Diluted EPS | $-0.03 | $-0.02 | $-0.04 | $-0.11 |
| Basic EPS | $-0.03 | $-0.02 | $-0.04 | $-0.11 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $142,000 | $-461,000 | $22,000 | $-1,646,000 |
| Total Unusual Items | $0 | $663,000 | $0 | $1,137,000 |
| Total Unusual Items Excluding Goodwill | $0 | $663,000 | $0 | $1,137,000 |
| Reconciled Depreciation | $206,000 | $194,000 | $218,000 | $262,000 |
| EBITDA (Bullshit earnings) | $142,000 | $202,000 | $22,000 | $-509,000 |
| EBIT | $-64,000 | $8,000 | $-196,000 | $-771,000 |
| Diluted Average Shares | $8,004,389 | $8,004,389 | $8,004,389 | $7,833,000 |
| Basic Average Shares | $8,004,389 | $8,004,389 | $8,004,389 | $7,833,000 |
| Diluted NI Availto Com Stockholders | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Research And Development | $657,000 | $511,000 | $492,000 | $695,000 |
| Selling General And Administration | $4,732,000 | $4,760,000 | $4,602,000 | $5,467,000 |
| Other Gand A | $3,516,000 | $3,514,000 | $3,357,000 | $4,084,000 |
| Other Special Charges | - | $-663,000 | - | $-1,137,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,651,000 | $-4,987,000 | $-5,398,000 | $-5,537,000 |
| Total Assets | $5,173,000 | $5,390,000 | $5,135,000 | $4,946,000 |
| Total Non Current Assets | $1,613,000 | $1,869,000 | $2,172,000 | $2,612,000 |
| Other Non Current Assets | $283,000 | $297,000 | $319,000 | $372,000 |
| Goodwill And Other Intangible Assets | $721,000 | $800,000 | $878,000 | $949,000 |
| Other Intangible Assets | $721,000 | $800,000 | $878,000 | $949,000 |
| Current Assets | $3,560,000 | $3,521,000 | $2,963,000 | $2,334,000 |
| Other Current Assets | $123,000 | $96,000 | $90,000 | $135,000 |
| Inventory | $1,149,000 | $1,263,000 | $1,384,000 | $1,184,000 |
| Receivables | $1,058,000 | $574,000 | $747,000 | $844,000 |
| Accounts Receivable | $1,058,000 | $574,000 | $747,000 | $844,000 |
| Cash Cash Equivalents And Short Term Investments | $1,230,000 | $1,588,000 | $742,000 | $171,000 |
| Cash And Cash Equivalents | $1,230,000 | $1,588,000 | $742,000 | $171,000 |
| Cash Financial | $1,230,000 | $1,588,000 | $742,000 | $171,000 |
| Non Current Prepaid Assets | - | - | $33,000 | $39,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $-3,000 | $-3,000 |
| Gross Accounts Receivable | - | - | $750,000 | $847,000 |
| Prepaid Assets | - | - | - | $135,000 |
| Debt | ||||
| Net Debt | $2,165,000 | $1,869,000 | $2,583,000 | $2,772,000 |
| Total Debt | $3,840,000 | $4,178,000 | $4,275,000 | $4,072,000 |
| Long Term Debt And Capital Lease Obligation | $115,000 | $445,000 | $720,000 | $950,000 |
| Current Debt And Capital Lease Obligation | $3,725,000 | $3,733,000 | $3,555,000 | $3,122,000 |
| Current Debt | $3,395,000 | $3,457,000 | $3,325,000 | $2,943,000 |
| Other Current Borrowings | - | - | - | $2,943,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,103,000 | $9,577,000 | $9,655,000 | $9,534,000 |
| Total Non Current Liabilities Net Minority Interest | $4,415,000 | $4,745,000 | $5,020,000 | $5,250,000 |
| Current Liabilities | $4,688,000 | $4,832,000 | $4,635,000 | $4,284,000 |
| Current Deferred Liabilities | $250,000 | $250,000 | $250,000 | - |
| Current Notes Payable | $3,395,000 | $3,457,000 | $3,325,000 | $2,943,000 |
| Payables And Accrued Expenses | $713,000 | $849,000 | $830,000 | $912,000 |
| Payables | $186,000 | $364,000 | $322,000 | $508,000 |
| Accounts Payable | $186,000 | $364,000 | $322,000 | $508,000 |
| Other Current Liabilities | - | - | $250,000 | $250,000 |
| Equity | ||||
| Common Stock Equity | $-3,935,000 | $-4,192,000 | $-4,525,000 | $-4,593,000 |
| Preferred Stock Equity | $5,000 | $5,000 | $5,000 | $5,000 |
| Total Equity Gross Minority Interest | $-3,930,000 | $-4,187,000 | $-4,520,000 | $-4,588,000 |
| Stockholders Equity | $-3,930,000 | $-4,187,000 | $-4,520,000 | $-4,588,000 |
| Retained Earnings | $-110,685,000 | $-110,476,000 | $-110,345,000 | $-110,014,000 |
| Preferred Securities Outside Stock Equity | $4,300,000 | $4,300,000 | $4,300,000 | $4,300,000 |
| Other | ||||
| Preferred Shares Number | $5,250,043 | $5,250,043 | $5,250,043 | $5,250,043 |
| Ordinary Shares Number | $8,004,389 | $8,004,389 | $8,004,389 | $8,004,389 |
| Share Issued | $8,004,389 | $8,004,389 | $8,004,389 | $8,004,389 |
| Tangible Book Value | $-4,656,000 | $-4,992,000 | $-5,403,000 | $-5,542,000 |
| Invested Capital | $-540,000 | $-735,000 | $-1,200,000 | $-1,650,000 |
| Working Capital | $-1,128,000 | $-1,311,000 | $-1,672,000 | $-1,950,000 |
| Capital Lease Obligations | $445,000 | $721,000 | $950,000 | $1,129,000 |
| Total Capitalization | $-3,930,000 | $-4,187,000 | $-4,520,000 | $-4,588,000 |
| Additional Paid In Capital | $106,742,000 | $106,276,000 | $105,812,000 | $105,413,000 |
| Capital Stock | $13,000 | $13,000 | $13,000 | $13,000 |
| Common Stock | $8,000 | $8,000 | $8,000 | $8,000 |
| Preferred Stock | $5,000 | $5,000 | $5,000 | $5,000 |
| Long Term Capital Lease Obligation | $115,000 | $445,000 | $720,000 | $950,000 |
| Current Capital Lease Obligation | $330,000 | $276,000 | $230,000 | $179,000 |
| Current Accrued Expenses | $527,000 | $485,000 | $508,000 | $404,000 |
| Net PPE | $609,000 | $772,000 | $975,000 | $1,252,000 |
| Accumulated Depreciation | $-2,327,000 | $-2,326,000 | $-2,219,000 | $-2,123,000 |
| Gross PPE | $2,936,000 | $3,098,000 | $3,194,000 | $3,375,000 |
| Leases | $625,000 | $617,000 | $558,000 | $549,000 |
| Construction In Progress | $12,000 | $12,000 | $0 | $1,000 |
| Other Properties | $352,000 | $557,000 | $727,000 | $868,000 |
| Machinery Furniture Equipment | $1,947,000 | $1,912,000 | $1,909,000 | $1,957,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-158,000 | $846,000 | $321,000 | $-1,342,000 |
| Operating Activities | ||||
| Operating Cash Flow | $13,000 | $929,000 | $332,000 | $-1,297,000 |
| Cash Flow From Continuing Operating Activities | $13,000 | $929,000 | $332,000 | $-1,297,000 |
| Operating Gains Losses | - | - | - | $-1,137,000 |
| Investing Activities | ||||
| Capital Expenditure | $-171,000 | $-83,000 | $-11,000 | $-45,000 |
| Investing Cash Flow | $-171,000 | $-83,000 | $-11,000 | $-45,000 |
| Cash Flow From Continuing Investing Activities | $-171,000 | $-83,000 | $-11,000 | $-45,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-200,000 | $0 | $250,000 | $824,000 |
| Cash Flow From Continuing Financing Activities | $-200,000 | $0 | $250,000 | $824,000 |
| Other | ||||
| Repayment Of Debt | $-200,000 | $0 | - | - |
| Interest Paid Supplemental Data | $10,000 | $6,000 | $3,000 | $5,000 |
| End Cash Position | $1,230,000 | $1,588,000 | $742,000 | $171,000 |
| Beginning Cash Position | $1,588,000 | $742,000 | $171,000 | $689,000 |
| Changes In Cash | $-358,000 | $846,000 | $571,000 | $-518,000 |
| Net Issuance Payments Of Debt | $-200,000 | $0 | $250,000 | $824,000 |
| Net Short Term Debt Issuance | $-200,000 | $0 | $250,000 | $350,000 |
| Short Term Debt Payments | $-200,000 | $0 | - | - |
| Net Intangibles Purchase And Sale | $-5,000 | $-3,000 | $-10,000 | $-22,000 |
| Purchase Of Intangibles | $-5,000 | $-3,000 | $-10,000 | $-22,000 |
| Net PPE Purchase And Sale | $-166,000 | $-80,000 | $-1,000 | $-23,000 |
| Purchase Of PPE | $-166,000 | $-80,000 | $-1,000 | $-23,000 |
| Change In Working Capital | $-809,000 | $-3,000 | $-227,000 | $-823,000 |
| Change In Other Current Liabilities | $-276,000 | $-229,000 | $-179,000 | $-342,000 |
| Change In Payables And Accrued Expense | $-136,000 | $19,000 | $-82,000 | $165,000 |
| Change In Accrued Expense | $42,000 | $-23,000 | $104,000 | $17,000 |
| Change In Payable | $-178,000 | $42,000 | $-186,000 | $148,000 |
| Change In Account Payable | $-178,000 | $42,000 | $-186,000 | $148,000 |
| Change In Prepaid Assets | $-27,000 | $-4,000 | $51,000 | $63,000 |
| Change In Inventory | $114,000 | $38,000 | $-114,000 | $-268,000 |
| Change In Receivables | $-484,000 | $173,000 | $97,000 | $-441,000 |
| Changes In Account Receivables | $-484,000 | $173,000 | $97,000 | $-441,000 |
| Other Non Cash Items | $343,000 | $302,000 | $273,000 | $406,000 |
| Stock Based Compensation | $466,000 | $464,000 | $399,000 | $644,000 |
| Provisionand Write Offof Assets | $14,000 | $103,000 | - | - |
| Asset Impairment Charge | $2,000 | $0 | $0 | $250,000 |
| Depreciation Amortization Depletion | $206,000 | $194,000 | $218,000 | $262,000 |
| Depreciation And Amortization | $206,000 | $194,000 | $218,000 | $262,000 |
| Net Income From Continuing Operations | $-209,000 | $-131,000 | $-331,000 | $-899,000 |
| Issuance Of Debt | - | $0 | $250,000 | $824,000 |
| Short Term Debt Issuance | - | $0 | $250,000 | $350,000 |
| Net Long Term Debt Issuance | - | - | $0 | $474,000 |
| Long Term Debt Issuance | - | - | $0 | $474,000 |
Fetched: 2026-02-02